abusesaffiliationarrow-downarrow-leftarrow-rightarrow-upattack-typeburgerchevron-downchevron-leftchevron-rightchevron-upClock iconclosedeletedevelopment-povertydiscriminationdollardownloademailenvironmentexternal-linkfacebookfiltergenderglobegroupshealthC4067174-3DD9-4B9E-AD64-284FDAAE6338@1xinformation-outlineinformationinstagraminvestment-trade-globalisationissueslabourlanguagesShapeCombined Shapeline, chart, up, arrow, graphLinkedInlocationmap-pinminusnewsorganisationotheroverviewpluspreviewArtboard 185profilerefreshIconnewssearchsecurityPathStock downStock steadyStock uptagticktooltiptwitteruniversalityweb

이 페이지는 한국어로 제공되지 않으며 English로 표시됩니다.

기업 응답

2015년 1월 9일

저자:
Gilead Sciences

Gilead Sciences' Response

...Gilead Sciences is working to help ensure access to its chronic hepatitis C medicines for all patients who can benefit from them. The company is... working with national governments to provide its branded medicines...As part of these efforts Gilead and its partners are designing measures to ensure that these high value curative medicines are not diverted...

Read full response here

타임라인